Can a short course of hepatitis c drugs before kidney transplant prevent infection?

NCT ID NCT05653232

Recruiting now Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at the best time to give hepatitis C medication to people without HCV who receive a kidney from an HCV-positive donor. One group starts the drug just before transplant and takes it for only 2 weeks; the other starts after transplant and takes it for 12 weeks. The goal is to see which approach prevents HCV infection more safely and effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sofosbuvir/Velpatasvir (SOF/VEL)
What this could lead to: If successful, this could show that starting HCV medication before transplant with a shorter course is safe and effective, potentially simplifying treatment and reducing costs.
What could go wrong: This is a relatively small, early-stage trial (120 participants) comparing two timing strategies, so results may not apply broadly. There is a risk of HCV transmission or liver injury despite prophylaxis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCV

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21205, United States
Loma Linda University Health
RECRUITING

Loma Linda, California, 92408, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States
University of California San Diego
RECRUITING

La Jolla, California, 92037, United States
University of Pittsburgh Medical Center
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
University of Utah Medical Center
RECRUITING

Salt Lake City, Utah, 84132, United States
University of Wisconsin, Madison
TERMINATED

Madison, Wisconsin, 53792, United States
Virginia Commonwealth University
RECRUITING

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.